Pharma + healthcare


Sankyo-Daiichi's move to block Fortis's sale surprised us: Fortis chairman Ravi Rajagopal

When Malaysia’s IHH Healthcare Berhad won the bid for Fortis, the hospital chain expected an end to months of turmoil. Its relief was short-lived. Daiichi Sankyo, the Japanese firm that is fighting an arbitration battle related to Ranbaxy against Shivinder and Malvinder Singh — former promoters of both Ranbaxy and Fortis — wants the Delhi High Court to block Fortis’s sale. In his first interview after being appointed chairman, Ravi Rajagopal opens up about this unexpected hurdle and what it means for Fortis’s future.


The knights of IHH

After a treacherous few months, which included two early losses to rival bidders, IHH Healthcare Berhad of Malaysia is set to take Fortis home. Who are the architects of what has been possibly the most nerve-racking deal in Indian healthcare history?


Superbugs have designs on India. Our preparation is inadequate.

Anti-microbial resistance (AMR) is a threat that is growing in severity. The country needs to develop better tests for early diagnosis, educate patients and doctors to not overuse antibiotics, and invest in new-generation antibiotics. At the moment, it is doing too little in all three areas.



[[/message]] [[#message]]